Strength and durability of antibody responses to BNT162b2 and CoronaVac - Cowling, Benjamin J.; Wong, Irene O. L.; Shiu, Eunice Y. C.; Lai, Amber Y. T.; Cheng, Samuel M. S.; Chaothai, Sara; Kwan, Kelvin K. H.; Martín-Sánchez, Mario; Poon, Leo L. M.; Ip, Dennis K. M.; Leung, Gabriel M.; Leung, Nancy H. L.; et al. (medRxiv, 2022)
We studied 2780 adults in Hong Kong who received CoronaVac inactivated virus vaccine (Sinovac) and BNT162b2 mRNA vaccine (“Comirnaty”, BioNTech/Fosun Pharma). We found stronger and more durable antibody responses to two doses of the mRNA vaccine, and slightly stronger initial antibody responses to each vaccine in younger adults and women.Competing Interest StatementBJC consults for AstraZeneca, Fosun Pharma, GSK, Moderna, Pfizer, Roche and Sanofi Pasteur. The authors report no other potential conflicts of interest.Funding StatementThis project was financially supported by the Health and Medical Research Fund of the Food and Health Bureau of the Hong Kong SAR Government (project nos. COVID1903001 and COVID190126), the Theme-based Research Scheme (project no. T11-712/19-N) from the Research Grants Council from the University Grants Committee of Hong Kong, and the Wellcome Trust (grant number: 221013/Z/20/Z). BJC is supported by an RGC Senior Research Fellowship (grant number: HKU SRFS2021-7S03).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocols were approved by the Institutional Review Board of the University of Hong KongI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors